A Phase III Randomized Open-label Sponsor-blinded Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01/D7029C00001)
Learn More About This Study
